• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai May 31 Wockhardt Ltd has received regulatory approval from the US Food and Drug Administration to market Terbinafine tablets, the generic copy of Novartis's brand Lamisil, in the US.

Terbinafine is used to treat fungal infections such as onychomycosis, a condition that affects the toenails or the fingernails, the company told the BSE.

Wockhardt will now be in a position to launch the drug in the US, shortly after the US patent on Lamisil expires on June 29.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Lanco's gas project gets CDM tag

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line